trending Market Intelligence /marketintelligence/en/news-insights/trending/luFLpKfZnh3KcYmHoJS6xQ2 content esgSubNav
In This List

Zimmer knee osteoarthritis treatment shows improvement in pain


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Zimmer knee osteoarthritis treatment shows improvement in pain

Zimmer Biomet Holdings Inc.'s trial of its nStride autologous protein solution kit to treat knee osteoarthritis showed significant improvement in the percentage change from baseline in pain scores.

The Progress 2 trial studied the safety and efficacy of the solution versus a single saline injection.

Investigators prepared the solution by using Zimmer Biomet's nStride APS Kit, which concentrates anti-inflammatory cytokines and growth factors from a sample of the patient's own blood, for delivery via a single intra-articular injection into the knee joint.

Patients receiving the kit-prepared solution reported 65% change in the Western Ontario and McMaster Universities Osteoarthritis Index, or WOMAC, pain index, compared to 41% for the patients receiving saline injections. On the Visual Analog Scale, the autologous protein users reported 49% improvement in pain scores, compared to a 13% improvement for the other group of patients.

The nStride APS kit is not commercially available in the U.S. The kit is marketed in the EU and in Japan.

Osteoarthritis is a degenerative joint disease that occurs when the cartilage or cushion between joints breaks down leading to pain, stiffness and swelling.